Remdesivir was developed by U.S. drugmaker Gilead Sciences Inc, which cut its 2020 revenue forecast last month, citing lower-than-expected demand and difficulty in predicting sales of the treatment. Cipla is among several firms licensed to make and sell generic versions in developing nations.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3lcwxl1
via IFTTT
0 comments:
Post a Comment